LAURA IVIE: Open Payments
NPI 1205135456 · IDAHO FALLS, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,076 in 54 payments from 19 companies in 2025. Trend: 2023 $506 · 2024 $700 · 2025 $1,076
Food & beverage: $1,076
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 10 | $212 |
| ABBVIE INC. | 12 | $204 |
| Vanda Pharmaceuticals Inc. | 3 | $92 |
| Novo Nordisk Inc | 5 | $84 |
| Phathom Pharmaceuticals, Inc. | 4 | $76 |
| Antares Pharma, Inc. | 3 | $65 |
| Aimmune Therapeutics, Inc. | 2 | $45 |
| GlaxoSmithKline, LLC. | 2 | $43 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $38 |
| Amgen Inc. | 2 | $34 |
Products named: Veozah, FANAPT, VRAYLAR, VOQUEZNA, QULIPTA, XYOSTED, ZENPEP, TRELEGY ELLIPTA.
Industry payments across ID — which companies pay providers there.
